DE3421789C2 - - Google Patents
Info
- Publication number
- DE3421789C2 DE3421789C2 DE3421789A DE3421789A DE3421789C2 DE 3421789 C2 DE3421789 C2 DE 3421789C2 DE 3421789 A DE3421789 A DE 3421789A DE 3421789 A DE3421789 A DE 3421789A DE 3421789 C2 DE3421789 C2 DE 3421789C2
- Authority
- DE
- Germany
- Prior art keywords
- polypeptides
- acetic acid
- thymus
- precipitate
- hours
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 84
- 210000001541 thymus gland Anatomy 0.000 claims description 39
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 36
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 35
- 239000003814 drug Substances 0.000 claims description 34
- 229920001184 polypeptide Polymers 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 21
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims description 20
- 239000002244 precipitate Substances 0.000 claims description 19
- 238000000605 extraction Methods 0.000 claims description 18
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 10
- 239000011592 zinc chloride Substances 0.000 claims description 10
- 235000005074 zinc chloride Nutrition 0.000 claims description 10
- 238000000265 homogenisation Methods 0.000 claims description 9
- 239000003960 organic solvent Substances 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims 2
- 239000007795 chemical reaction product Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 description 20
- 239000000843 powder Substances 0.000 description 19
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
- 239000000243 solution Substances 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 239000013543 active substance Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 239000000126 substance Substances 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 206010020751 Hypersensitivity Diseases 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 7
- 210000001789 adipocyte Anatomy 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 244000309466 calf Species 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 241000282412 Homo Species 0.000 description 4
- 229920005654 Sephadex Polymers 0.000 description 4
- 239000012507 Sephadex™ Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 230000008929 regeneration Effects 0.000 description 4
- 238000011069 regeneration method Methods 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000002523 gelfiltration Methods 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- CKLJMWTZIZZHCS-UHFFFAOYSA-N Aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 230000011132 hemopoiesis Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 230000000771 oncological effect Effects 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000022558 protein metabolic process Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000006670 Multiple fractures Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000001720 action spectrum Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- -1 carboxyl cation Chemical class 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000013210 hematogenous Diseases 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000037189 immune system physiology Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229940053973 novocaine Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57581—Thymosin; Related peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Obesity (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB08516697A GB2177402A (en) | 1985-07-02 | 1985-07-02 | Thymus-gland preparation and method for producing same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE3421789A1 DE3421789A1 (de) | 1985-12-12 |
| DE3421789C2 true DE3421789C2 (en, 2012) | 1988-10-06 |
Family
ID=10581651
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19843421789 Granted DE3421789A1 (de) | 1985-07-02 | 1984-06-12 | Arzneimittel aus dem thymus und verfahren zu dessen herstellung |
Country Status (5)
| Country | Link |
|---|---|
| JP (1) | JPS60258120A (en, 2012) |
| CH (1) | CH659586A5 (en, 2012) |
| DE (1) | DE3421789A1 (en, 2012) |
| FR (1) | FR2583982B1 (en, 2012) |
| GB (1) | GB2177402A (en, 2012) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1196958B (it) * | 1986-07-10 | 1988-11-25 | Ellem Ind Farmaceutica | Derivato di timo attivo per via orale, procedimenti per la sua preparazione e relative composizioni farmaceutiche |
| DE3633651A1 (de) * | 1986-10-03 | 1988-04-14 | Alfred Dr Dick | Verwendung von fraktionen aus thymus- und milzextrakten zur behandlung der psoriasis |
| US5728680A (en) | 1987-12-30 | 1998-03-17 | Cytoven J.V. | Methods for normalizing numbers of lymphocytes |
| US5811399A (en) * | 1988-12-14 | 1998-09-22 | Cytran, Inc. | Pharmaceutical dipeptide compositions and methods of use thereof: immunodepressants |
| JPH0365161A (ja) * | 1989-08-01 | 1991-03-20 | Marudai Shokuhin Kk | 機能性食品 |
| US6100380A (en) * | 1991-10-28 | 2000-08-08 | Cytran, Inc. | Immunomodulating peptides and methods of use |
| US6066622A (en) * | 1991-10-28 | 2000-05-23 | Cytran, Inc. | Immunomodulating peptides and methods of use |
| RU2107692C1 (ru) | 1995-06-07 | 1998-03-27 | Дейгин Владислав Исакович | Пептид и способ его получения |
| RU2107691C1 (ru) * | 1995-03-02 | 1998-03-27 | Дейгин Владислав Исакович | Пептид и способ его получения |
| RU2121480C1 (ru) * | 1996-02-28 | 1998-11-10 | Закрытое акционерное общество Центр "Пептос" | Пептид, обладающий влиянием на регенерацию кроветворной и иммунной систем, и фармацевтическая композиция на его основе |
| RU2149006C1 (ru) * | 1998-06-19 | 2000-05-20 | Внуков Владислав Анатольевич | Способ получения иммуномодуляторов |
| RU2295963C1 (ru) * | 2005-10-18 | 2007-03-27 | Закрытое акционерное общество Научно-производственное предприятие "Тринита" | Способ получения иммуностимулятора |
| RU2320354C2 (ru) * | 2005-12-15 | 2008-03-27 | Общество с ограниченной ответственностью "ЛАЙФЭЛИКСИР" | Способ получения иммуностимулирующих тимусных полипептидов, влияющих на гемопоэз |
| RU2290936C1 (ru) * | 2006-01-31 | 2007-01-10 | Общество С Ограниченной Ответственностью "Сиа Пептайдс" | Способ получения средства для поддерживающей терапии, обладающего тканеспецифической активностью |
| RU2327475C1 (ru) * | 2006-11-28 | 2008-06-27 | Общество с ограниченной ответственностью Научно-производственное предприятие "ЭргоБио" | Способ получения иммуноактивных полипептидов/пептидов, обладающих иммунокорригирующими свойствами |
| RU2648466C1 (ru) * | 2016-11-01 | 2018-03-26 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Воронежский государственный университет инженерных технологий" (ФГБОУ ВО "ВГУИТ") | Способ получения биогенного стимулятора для лечения и профилактики заболеваний сельскохозяйственных животных |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU1218521A1 (ru) * | 1980-06-16 | 1994-06-30 | В.Г. Морозов | Способ получения полипептидов |
| FR2492663B1 (fr) * | 1980-10-24 | 1985-11-08 | Vtoroi Mo G | Produit medicamenteux regulateur du t-systeme de l'immunite et son procede de preparation |
| ATE22801T1 (de) * | 1981-11-26 | 1986-11-15 | Heinrich Dr Med Ollendiek | Verfahren zur extraktion der thymusdruese. |
| JPS59501786A (ja) * | 1982-09-20 | 1984-10-25 | エンド−フイン，インコ−ポレイテツド | 免疫刺戟体 |
-
1984
- 1984-05-24 CH CH2550/84A patent/CH659586A5/de not_active IP Right Cessation
- 1984-06-04 JP JP59113234A patent/JPS60258120A/ja active Granted
- 1984-06-12 DE DE19843421789 patent/DE3421789A1/de active Granted
-
1985
- 1985-07-01 FR FR858510002A patent/FR2583982B1/fr not_active Expired
- 1985-07-02 GB GB08516697A patent/GB2177402A/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| GB8516697D0 (en) | 1985-08-07 |
| GB2177402A (en) | 1987-01-21 |
| FR2583982A1 (fr) | 1987-01-02 |
| DE3421789A1 (de) | 1985-12-12 |
| JPS60258120A (ja) | 1985-12-20 |
| CH659586A5 (de) | 1987-02-13 |
| JPH0247966B2 (en, 2012) | 1990-10-23 |
| FR2583982B1 (fr) | 1989-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3421789C2 (en, 2012) | ||
| DE3689909T2 (de) | Verwendung eines GHL-Cu enthaltenden Stoffes zur Herstellung eines Arzneimittels für Wunden. | |
| DE60003837T2 (de) | Tetrapeptid, das die funktionelle aktivität von neuronen stimuliert, dieses enthaltendes pharmakologisches mittel und seine verwendung | |
| CH640140A5 (de) | Verfahren zur herstellung von intravenoes injizierbarem gamma-globulin. | |
| DE3027105A1 (de) | Verfahren zur herstellung eines die proliferation und differenzierung menschlicher granulopoetischer stammzellen stimulierenden faktors | |
| EP0346501B1 (de) | Arzneimittelzubereitung zur behandlung des immunmangels | |
| DE2628914C2 (en, 2012) | ||
| DE3687097T2 (de) | Therapeutisches mittel zur behandlung haematopoietischer krankheiten. | |
| DE1949195A1 (de) | Verfahren zur Herstellung deproteinisierter Bluextrakte mit Heilwirkung | |
| EP0101063A2 (de) | Neues Polypeptid mit Wirkung auf das Immunsystem, Verfahren zu seiner Isolierung und Reinigung, seine Verwendung und dieses enthaltende Mittel | |
| EP0894094A1 (de) | Verfahren zur gewinnung eines komplexes aus wachstumsfaktoren | |
| DE3850262T2 (de) | Verfahren zur herstellung einer physiologisch aktiven substanz aus samenschalen von föhren und ein gegen infektionen aktives mittel, hauptsächlich auf der basis von diesem extrakt. | |
| DE3306944C2 (en, 2012) | ||
| DE1940130C2 (de) | Verfahren zur Reinigung von Insulin, nach diesem Verfahren gereinigtes Insulin und dessen Verwendung | |
| DE1076888B (de) | Verfahren zur Gewinnung atmungsfoerdernder Wirkstoffe fuer therapeutische Zwecke | |
| DE2234832C2 (de) | Proteinfreies Hormonkonzentrat von Säugetier-Nebenschilddrüsen, dessen Herstellung und dieses Hormonkonzentrat enthaltende pharmazeutische Präparate | |
| DE2558537C2 (de) | Verfahren zum Isolieren von Substanzen mit insulinähnlicher Wirksamkeit aus Blut oder Blutbestandteilen von Kälbern oder Schweinen | |
| DE3914354C1 (en, 2012) | ||
| DE3539775C2 (de) | Neues Lymphokin, gegen dieses Lymphokin spezifische Antikörper, Verfahren zu ihrer Herstellung und ihre Verwendung | |
| DE2515666C3 (de) | Piasminreiche Gammaglobulinfraktion, Verfahren zu deren Herstellung und das Verfahrensprodukt enthaltendes Gammaglobulinpräparat | |
| DE69126563T2 (de) | Verwendung einer Mischung von Peptiden and Aminosäuren für die Prophylaxis oder Behandlung von Dementia | |
| AT392003B (de) | Verfahren zur herstellung eines insbesondere zur wundheilung oder zur behandlung in der geriatrie verwendbaren wirkstoffes aus saeugetierblut durch papainhydrolyse und ein einen solchen wirkstoff enthaltendes praeparat | |
| CH640244A5 (en) | Biologically active substance | |
| CH640865A5 (de) | Glykoproteid des menschlichen urins, verfahren zu seiner herstellung und mittel zur bekaempfung von leukozytopenie. | |
| DE1296306B (de) | Verfahren zur Gewinnung von Proteinstoffen mit biologischer Wirkung auf das Nervensystem |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8110 | Request for examination paragraph 44 | ||
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |